Outcomes following cardiac sympathetic denervation in patients with structural heart disease and refractory ventricular arrhythmia.
Sebastian KönigThomas SchröterMichael A BorgerLivio BertagnolliSotirios NediosAngeliki DarmaGerhard HindricksArash AryaBorislav DinovPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2022)
The CSD showed additional moderate efficacy to suppress VAs, when performed as a bailout therapy after previously unsuccessful catheter ablation. At 9 months, it was associated with freedom of ICD shocks in two-thirds of patients. In a population with many comorbidities, the rate of CSD-related complications was acceptable, although there was an overall high risk of procedure unrelated adverse events and death.